LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,125
تعداد مقالات10,314
تعداد مشاهده مقاله43,473,644
تعداد دریافت فایل اصل مقاله9,718,835
Güren, Ali Kaan, Majidova, Nargiz, Çakır, İclal, Sever, Nadiye, Kocaaslan, Erkam, Erel, Pınar, Ağyol, Yeşim, Çelebi, Abdussamed, Arıkan, Rukiye, Işık, Selver, Sarı, Murat, Ercelep, Özlem, Bayoğlu, İbrahim Vedat, Köstek, Osman. (1403). Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients. سامانه مدیریت نشریات علمی, (), -. doi: 10.30476/mejc.2024.102063.2071
Ali Kaan Güren; Nargiz Majidova; İclal Çakır; Nadiye Sever; Erkam Kocaaslan; Pınar Erel; Yeşim Ağyol; Abdussamed Çelebi; Rukiye Arıkan; Selver Işık; Murat Sarı; Özlem Ercelep; İbrahim Vedat Bayoğlu; Osman Köstek. "Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients". سامانه مدیریت نشریات علمی, , , 1403, -. doi: 10.30476/mejc.2024.102063.2071
Güren, Ali Kaan, Majidova, Nargiz, Çakır, İclal, Sever, Nadiye, Kocaaslan, Erkam, Erel, Pınar, Ağyol, Yeşim, Çelebi, Abdussamed, Arıkan, Rukiye, Işık, Selver, Sarı, Murat, Ercelep, Özlem, Bayoğlu, İbrahim Vedat, Köstek, Osman. (1403). 'Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients', سامانه مدیریت نشریات علمی, (), pp. -. doi: 10.30476/mejc.2024.102063.2071
Güren, Ali Kaan, Majidova, Nargiz, Çakır, İclal, Sever, Nadiye, Kocaaslan, Erkam, Erel, Pınar, Ağyol, Yeşim, Çelebi, Abdussamed, Arıkan, Rukiye, Işık, Selver, Sarı, Murat, Ercelep, Özlem, Bayoğlu, İbrahim Vedat, Köstek, Osman. Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients. سامانه مدیریت نشریات علمی, 1403; (): -. doi: 10.30476/mejc.2024.102063.2071

Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients

Middle East Journal of Cancer
مقالات آماده انتشار، پذیرفته شده، انتشار آنلاین از تاریخ 21 مرداد 1403    اصل مقاله (350.47 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/mejc.2024.102063.2071
نویسندگان
Ali Kaan Güren* 1؛ Nargiz Majidova1؛ İclal Çakır2؛ Nadiye Sever1؛ Erkam Kocaaslan1؛ Pınar Erel1؛ Yeşim Ağyol1؛ Abdussamed Çelebi1؛ Rukiye Arıkan1؛ Selver Işık1؛ Murat Sarı1؛ Özlem Ercelep1؛ İbrahim Vedat Bayoğlu1؛ Osman Köstek1
1Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey
2Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey
چکیده
Background: Bevacizumab, used in the treatment of metastatic colorectal cancer (mCRC), has an angiogenesis inhibitory effect. Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II type 1 receptor blockers (ARBs) used in the treatment of arterial hypertension demonstrate antitumoural effects through different pathways. In our study, we aimed to investigate whether ACEi or ARB has a synergistic effect on survival in patients receiving bevacizumab treatment.
Method: A total of 208 patients receiving Bevacizumab for mCRC were included in this retrospective study. We divided the patients into two groups as Renin Angiotensin System inhibitors (RASi) users and non-users. We compared the progressin-free survival (PFS) and overall survival (OS) times between the 2 groups. Kaplan-Meier and Cox regression analyses were used for statistical analyses.
Results: In this study, 53 patients with RASIs and 155 without RASIs were included. The RASIs group had a median PFS of 8.66 months, while the non-RASIs group had a median of 6.67 months (P = 0.034; P < 0.05). The RASIs group had a median OS of 24.86 months, while the non-RASIs group had a 18.71 months (P = 0.039; P < 0.05). In the RASIs group, multivariate analysis showed PFS [Hazard Ratio (HR): 1.425 (95% Confidence Interval (CI): 1.037-1.959), P = 0.029] and OS [HR: 1.371 (95% CI: 1.001-1.897), P = 0.044].
Conclusion: Bevacizumab in combination with ACEi or ARBs prolongs PFS and OS in patients with mCRC. Prioritising ACEi and ARBs in patients with mCRC and arterial hypertension provides a survival advantage. These findings should be supported through further studies involving larger patient populations and addressing other factors that may affect prognosis.

تازه های تحقیق

Ali Kaan Güren (Google Scholar)

کلیدواژه‌ها
Colorectal neoplasms؛ Bevacizumab؛ Angiotensin-converting enzyme inhibitors؛ Angiotensin II type 1 receptor blockers
مراجع
  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660. PMID: 33538338.
  2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi: 10.3322/caac.21763. PMID: 36633525.
  3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80. doi: 10.1016/S0140-6736(21)01330-1. Erratum in: Lancet. 2022;399(10324):520. PMID: 34450083; PMCID: PMC8446938.
  4. Bayram F, Demir Ö, Sabuncu T, Eren MA, Gedik AV, Çorapçıoğlu D, et al. Prevalence and awareness of hypertension in seven distinct geographic regions of Turkey: The SEMT HT study. Turk J Endocrinol Metab. 2021;25:1-10. doi: 10.25179/tjem.2020-78532.
  5. Aydoğdu S, Güler K, Bayram F, Altun B, Derici Ü, Abacı A, et al. 2019 Turkish Hypertension Consensus Report. [in Turkish] Turk Kardiyol Dern Ars. 2019;47(6):535-46. doi: 10.5543/tkda.2019.62565. PMID: 31483311.
  6. Yang J, Yang X, Gao L, Zhang J, Yi C, Huang Y. The role of the renin-angiotensin system inhibitors in malignancy: a review. Am J Cancer Res. 2021;11(3):884-97. PMID: 33791161; PMCID: PMC7994166.
  7. Jiang H, Tai Z, Chen Z, Zhu Q, Bao L. Clinical applicability of renin-angiotensin system inhibitors in cancer treatment. Am J Cancer Res. 2021;11(2):318-36. PMID: 33575074; PMCID: PMC7868760.
  8. Sobczuk P, Szczylik C, Porta C, Czarnecka AM. Renin angiotensin system deregulation as renal cancer risk factor. Oncol Lett. 2017;14(5):5059-68. doi: 10.3892/ol.2017.6826. PMID: 29098020; PMCID: PMC5652144.
  9. Matsushima-Otsuka S, Fujiwara-Tani R, Sasaki T, Ohmori H, Nakashima C, Kishi S, et al. Significance of intranuclear angiotensin-II type 2 receptor in oral squamous cell carcinoma. Oncotarget. 2018;9(93):36561-74. doi: 10.18632/oncotarget.26337. PMID: 30564297; PMCID: PMC6290968.
  10. Yang D, Huo Q, Luan T, Wang J, Tang Z, Wang H. Effects of angiotensin ınhibitor valsartan on the expression of the angiotensin II 1 receptor, matrix metalloproteinases -2 and -9 in human bladder cancer cell lines. Clin Lab. 2016;62(8):1435-42. doi: 10.7754/Clin.Lab.2016.151131. PMID: 28164602.
  11. Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72(2):338-44. doi: 10.1136/gutjnl-2022-327736. PMID: 36604116.
  12. Li M, Kroetz DL. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152-60. doi: 10.1016/j.pharmthera.2017.08.012. PMID: 28882537; PMCID: PMC5785435.
  13. de Miranda FS, Guimarães JPT, Menikdiwela KR, Mabry B, Dhakal R, Rahman RL, et al. Breast cancer and the renin-angiotensin system (RAS): Therapeutic approaches and related metabolic diseases. Mol Cell Endocrinol. 2021;528:111245. doi: 10.1016/j.mce.2021.111245. PMID: 33753205.
  14. Childers WK. Interactions of the renin-angiotensin system in colorectal cancer and metastasis. Int J Colorectal Dis. 2015;30(6):749-52. doi: 10.1007/s00384-014-2118-1. PMID: 25592047.
  15. Rosenthal T, Gavras I. Renin-angiotensin ınhibition in combating malignancy: A review. Anticancer Res. 2019;39(9):4597-602. doi: 10.21873/anticanres.13639. PMID: 31519556.
  16. Nuzzo PV, Adib E, Weise N, Curran C, Stewart T, Freeman D, et al. Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors. Clin Genitourin Cancer. 2022;20(4):301-6. doi: 10.1016/j.clgc.2022.04.012. PMID: 35614012; PMCID: PMC10013974.
  17. Moriyama S, Hieda M, Kisanuki M, Kawano S, Yokoyama T, Fukata M, et al. Effect of renin-angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy. Open Heart. 2022;9(2):e002135. doi: 10.1136/openhrt-2022-002135. PMID: 36600585; PMCID: PMC9743396.
  18. Osumi H, Matsusaka S, Wakatsuki T, Suenaga M, Shinozaki E, Mizunuma N. Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Mol Clin Oncol. 2015;3(6):1295-300. doi: 10.3892/mco.2015.630. PMID: 26807236; PMCID: PMC4665652.
  19. Mao CL, Seow KM, Chen KH. The utilization of bevacizumab in patients with advanced ovarian cancer: A systematic review of the mechanisms and effects. Int J Mol Sci. 2022;23(13):6911. doi: 10.3390/ijms23136911. PMID: 35805914; PMCID: PMC9266930.
  20. Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: A meta-analysis of more than 20 000 patients. J Am Heart Assoc. 2017;6(8):e006278. doi: 10.1161/JAHA.117.006278. PMID: 28862931; PMCID: PMC5586462.
آمار
تعداد مشاهده مقاله: 40
تعداد دریافت فایل اصل مقاله: 35


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب